{"protocolSection": {"identificationModule": {"nctId": "NCT02151383", "orgStudyIdInfo": {"id": "CRLX030A2208"}, "secondaryIdInfos": [{"id": "2013-002847-28", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure", "officialTitle": "Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure", "acronym": "RELAX-PEDS-PK"}, "statusModule": {"statusVerifiedDate": "2019-05", "overallStatus": "TERMINATED", "whyStopped": "Study terminated early based on Adult AHF study CRLX030A2301 results", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-09-05", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-04-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-04-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-05-28", "studyFirstSubmitQcDate": "2014-05-28", "studyFirstPostDateStruct": {"date": "2014-05-30", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-09-27", "resultsFirstSubmitQcDate": "2019-06-01", "resultsFirstPostDateStruct": {"date": "2019-06-25", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2019-06-01", "lastUpdatePostDateStruct": {"date": "2019-06-25", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of the study was to evaluate the safety, tolerability and pharmacokinetics of an intravenous infusion of serelaxin on top of standard of care therapy, in pediatric patients with acute heart failure (AHF)", "detailedDescription": "The study was terminated early and the pediatric development of serelaxin in the treatment of acute heart failure (AHF) discontinued, following the results of the phase III study RELAX-AHF-2 (CRLX030A2301/NCT01870778) study in adult patients with AHF. Whilst no new safety concerns associated with serelaxin were observed, the study in adults did not meet either of its primary endpoints"}, "conditionsModule": {"conditions": ["Acute Heart Failure"], "keywords": ["Acute heart failure", "RELAX-AHF-PEDIATRIC PK", "AHF"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 12, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Serelaxin", "type": "EXPERIMENTAL", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours.", "interventionNames": ["Drug: Serelaxin"]}], "interventions": [{"type": "DRUG", "name": "Serelaxin", "description": "Serelaxin was administered intravenously for up to 48 hours.", "armGroupLabels": ["Serelaxin"], "otherNames": ["RLX030"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Patients With Treatment Emergent Adverse Events, Serious Adverse Events and Death", "description": "Number of patients with treatment emergent adverse events (including confirmed systolic blood pressure decreases and worsening heart failure), serious adverse events and death were reported.", "timeFrame": "through 28 days + 30 days SAE follow up after completion or discontinuation from the study"}, {"measure": "Pharmacokinetic Concentration for Low Dose 3-10-30 ug/kg/Day", "description": "Pharmacokinetic (PK) concentration was presented as the surrogate for PK parameters, the original primary endpoint, due to the unavailability of the PK parameters Css and CL. Serelaxin concentration was determined in serum by a validated Enzyme Linked ImmunoSorbent Assay (ELISA) based upon the commercially available kit from R\\&D Systems (Catalogue No. DRL200). The ELISA method used a monoclonal antibody specific for human H2 relaxin as the capture reagent and an enzyme-linked polyclonal antibody specific for human.", "timeFrame": "at 0, 2, 16, 22, 32, 40, 48 hr. during the infusion, at 0.5, 4, 8 hours post infusion or study drug discontinuation, and on day 28"}, {"measure": "Pharmacokinetic Concentration for High Dose (10-30-100 ug/kg/Day)", "description": "Pharmacokinetic (PK) concentration was presented as the surrogate for PK parameters, the original primary endpoint, due to the unavailability of the PK parameters Css and CL. Serelaxin concentration was determined in serum by a validated Enzyme Linked ImmunoSorbent Assay (ELISA) based upon the commercially available kit from R\\&D Systems (Catalogue No. DRL200). The ELISA method used a monoclonal antibody specific for human H2 relaxin as the capture reagent and an enzyme-linked polyclonal antibody specific for human.", "timeFrame": "at 0, 2, 16, 22, 32, 40, 48 hr. during the infusion, at 0.5, 4, 8 hours post infusion or study drug discontinuation, and on day 28"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Left Arterial Pressure for Low Dose (3-10-30 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study.", "timeFrame": "baseline, prior to each dose escalation, and at 24 hr. post end of infusion"}, {"measure": "Change From Baseline in Mean Left Arterial Pressure for High Dose (10 -30-100 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study.", "timeFrame": "baseline, prior to each dose escalation, and at 24 hr. post end of infusion"}, {"measure": "Change From Baseline in Mean Pulmonary Artery Pressure (PAP- Systolic and Diastolic) for Low Dose (3-10-30 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day3: 24 hours post infusion"}, {"measure": "Change From Baseline in Mean Pulmonary Artery Pressure (PAP- Systolic and Diastolic) for High Dose (10-30-100 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "timeFrame": "Day 1: hour 0 and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion"}, {"measure": "Change From Baseline in Mean Central Venous Pressure for Low Dose (3-10-30 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion"}, {"measure": "Change From Baseline in Mean Central Venous Pressure for High Dose (10-30-100 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion"}, {"measure": "Baseline and Change From Baseline in Mean Central Venous Pressure and Arterial Oxygen Saturation for Low Dose (3-10-30 ug/kg/Day)", "description": "This analysis includes central venous and arterial oxygen saturation measurement, yielding a calculation of the arterio-venous oxygen extraction, where available at each time point. If no arterial access was available, then arterial oxygen saturation measurement data were obtained using a pulse oximeter. The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion"}, {"measure": "Baseline and Change From Baseline in Mean Central Venous Pressure and Arterial Oxygen Saturation for High Dose (10-30-100 ug/kg/Day)", "description": "This analysis includes central venous and arterial oxygen saturation measurement, yielding a calculation of the arterio-venous oxygen extraction, where available at each time point. If no arterial access was available, then arterial oxygen saturation measurement data were obtained using a pulse oximeter.\n\nThe evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion"}, {"measure": "Baseline and Change From Baseline in Mean Urine Output for Low Dose (3-10-30 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion"}, {"measure": "Baseline and Change From Baseline in Mean Urine Output for High Dose (10-30-100 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion"}, {"measure": "Baseline and Change From Baseline in Mean Blood Lactate Levels (Arterial Blood) for Low Dose (3-10-30 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion"}, {"measure": "Baseline and Change From Baseline in Mean Blood Lactate Levels (Central Venous Blood) for Low Dose (3-10-30 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion"}, {"measure": "Baseline and Change From Baseline in Mean Blood Lactate Levels (Arterial Blood) for High Dose (10-30-100 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion"}, {"measure": "Baseline and Change From Baseline in Mean Blood Lactate Levels (Central Venous Blood) for High Dose (10-30-100 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion"}]}, "eligibilityModule": {"eligibilityCriteria": "Key Inclusion criteria:\n\n* Body weight \u22652.5 kg to \u2264120 kg\n* Hospitalized in an intensive care unit or step-down unit with the following:\n* - Signs and symptoms of acute heart failure of any etiology\n* - Stable dose of vasoactive and/or inotropic drugs\n* - For non-surgical patients echocardiographic evidence of reduced ventricular function (ejection fraction \\<50% or fractional shortening \\<28%)\n* Systolic blood pressure (SBP) \u226525th percentile SBP for age and gender.\n\nKey Exclusion criteria:\n\n* Moderate to severe left ventricular outflow tract, mitral stenosis, or aortic arch obstruction\n* Single ventricle physiology\n* Fixed pulmonary hypertension\n* Blood lactate levels \\>5 mmol/L at screening\n* Birth \\< 36 weeks post-conceptual age (for patients \\<1year old)\n* Confirmed or clinically suspected systemic infection or severe localized infection\n* Dyspnea or acute lung injury primarily due to non-cardiac causes\n* Patients with severe renal impairment, those known to have significant renal disease and those having renal replacement therapy\n* High use of inotropic and/or vasoactive agents at screening\n* Electrocardiographic abnormalities\n* Solid organ transplant recipient within 1 year of transplantation or one who presents with severe organ rejection", "healthyVolunteers": false, "sex": "ALL", "maximumAge": "17 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Denver", "state": "Colorado", "zip": "80218", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Novartis Investigative Site", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Novartis Investigative Site", "city": "Bronx", "state": "New York", "zip": "10467", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Novartis Investigative Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Novartis Investigative Site", "city": "Charleston", "state": "South Carolina", "zip": "29425", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "13353", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Freiburg", "zip": "79106", "country": "Germany", "geoPoint": {"lat": 47.9959, "lon": 7.85222}}, {"facility": "Novartis Investigative Site", "city": "Muenchen", "zip": "80636", "country": "Germany", "geoPoint": {"lat": 51.60698, "lon": 13.31243}}, {"facility": "Novartis Investigative Site", "city": "Gen\u00e8ve", "zip": "1211", "country": "Switzerland", "geoPoint": {"lat": 46.20222, "lon": 6.14569}}, {"facility": "Novartis Investigative Site", "city": "London", "zip": "WC1N 1EH", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED", "description": "Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.\n\nThis trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 18 patients were assigned to study treatment. 6 patients were identified with GCP violations; hence, only 12 patients were included in disposition.", "groups": [{"id": "FG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "FG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "FG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Low-dose", "achievements": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "High-dose", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety Set", "groups": [{"id": "BG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "BG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "BG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "12"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "11.1", "spread": "3.23"}, {"groupId": "BG001", "value": "2.7", "spread": "1.53"}, {"groupId": "BG002", "value": "0.7", "spread": "NA", "comment": "Standard Deviation cannot be calculated when there is one patient."}, {"groupId": "BG003", "value": "8.1", "spread": "5.17"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "11"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "7"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Patients With Treatment Emergent Adverse Events, Serious Adverse Events and Death", "description": "Number of patients with treatment emergent adverse events (including confirmed systolic blood pressure decreases and worsening heart failure), serious adverse events and death were reported.", "populationDescription": "All appropriately consented enrolled subjects who were exposed to study drug regardless of the exposure and have at least one post-baseline safety assessment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Patients", "timeFrame": "through 28 days + 30 days SAE follow up after completion or discontinuation from the study", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "at least one Adverse Event", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Serious Adverse Event", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Death", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Pharmacokinetic Concentration for Low Dose 3-10-30 ug/kg/Day", "description": "Pharmacokinetic (PK) concentration was presented as the surrogate for PK parameters, the original primary endpoint, due to the unavailability of the PK parameters Css and CL. Serelaxin concentration was determined in serum by a validated Enzyme Linked ImmunoSorbent Assay (ELISA) based upon the commercially available kit from R\\&D Systems (Catalogue No. DRL200). The ELISA method used a monoclonal antibody specific for human H2 relaxin as the capture reagent and an enzyme-linked polyclonal antibody specific for human.", "populationDescription": "participants with available data differed across time points", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "at 0, 2, 16, 22, 32, 40, 48 hr. during the infusion, at 0.5, 4, 8 hours post infusion or study drug discontinuation, and on day 28", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Day 1 hour 0 during infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.083", "spread": "NA", "comment": "CV% geo-mean is derived as a function of log-transformed data. At least one patient had an outcome value = 0, causing the logarithm of the outcome value and thus CV% geo-mean undefined (note: logarithm of data can only be defined for a value \\> 0)"}, {"groupId": "OG001", "value": "NA", "spread": "NA", "comment": "All outcome value(s) = 0. Therefore, Geometric mean and CV% geo-mean are not populated."}, {"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "All outcome value(s) = 0. Therefore, Geometric mean and CV% geo-mean are not populated."}]}]}, {"title": "Day 1 hour 2 during infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.514", "spread": "23.600"}, {"groupId": "OG001", "value": "0.375", "spread": "176.043"}, {"groupId": "OG002", "value": "1.250"}]}]}, {"title": "Day 1 hour 16 during infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.795", "spread": "66.578"}, {"groupId": "OG001", "value": "0.772", "spread": "41.016"}, {"groupId": "OG002", "value": "0.571"}]}]}, {"title": "Day 1 hour 22 during infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.868", "spread": "23.134"}, {"groupId": "OG001", "value": "2.183", "spread": "11.690"}, {"groupId": "OG002", "value": "3.810"}]}]}, {"title": "Day 2 hour 32 during infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.208", "spread": "32.740"}, {"groupId": "OG001", "value": "2.155", "spread": "13.492"}, {"groupId": "OG002", "value": "NA", "spread": "NA", "comment": "All outcome value(s) = 0. Therefore, Geometric mean and CV% geo-mean are not populated"}]}]}, {"title": "Day 2 hour 40 during infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.891", "spread": "49.702"}, {"groupId": "OG001", "value": "5.513", "spread": "17.664"}, {"groupId": "OG002", "value": "0.236"}]}]}, {"title": "Day 2 hour 48 during infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "6.315", "spread": "60.265"}, {"groupId": "OG001", "value": "5.365", "spread": "16.148"}, {"groupId": "OG002", "value": "9.010"}]}]}, {"title": "Day 3 hour 48.5 post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.107", "spread": "39.153"}, {"groupId": "OG001", "value": "3.999", "spread": "22.826"}, {"groupId": "OG002", "value": "66.600"}]}]}, {"title": "Day 3 hour 52 post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.751", "spread": "26.134"}, {"groupId": "OG001", "value": "0.956", "spread": "12.016"}, {"groupId": "OG002", "value": "2.440"}]}]}, {"title": "Day 3 hour 56 post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.420", "spread": "42.285"}, {"groupId": "OG001", "value": "0.416", "spread": "59.458"}, {"groupId": "OG002", "value": "0.470"}]}]}, {"title": "Day28 hour 648 n=2,1,0 post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "All outcome value(s) = 0. Therefore, Geometric mean and CV% geo-mean are not populated"}, {"groupId": "OG001", "value": "NA", "comment": "All outcome value(s) = 0. Therefore, Geometric mean and CV% geo-mean are not populated"}]}]}]}, {"type": "PRIMARY", "title": "Pharmacokinetic Concentration for High Dose (10-30-100 ug/kg/Day)", "description": "Pharmacokinetic (PK) concentration was presented as the surrogate for PK parameters, the original primary endpoint, due to the unavailability of the PK parameters Css and CL. Serelaxin concentration was determined in serum by a validated Enzyme Linked ImmunoSorbent Assay (ELISA) based upon the commercially available kit from R\\&D Systems (Catalogue No. DRL200). The ELISA method used a monoclonal antibody specific for human H2 relaxin as the capture reagent and an enzyme-linked polyclonal antibody specific for human.", "populationDescription": "No data available for Cohort 2 and 3", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "at 0, 2, 16, 22, 32, 40, 48 hr. during the infusion, at 0.5, 4, 8 hours post infusion or study drug discontinuation, and on day 28", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "Day 1 hour 0 during infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "At least one outcome value = 0. Geometric mean is calculated based on the logarithm of the outcome values, and is not populated if any outcome value = 0. CV is not available due to insufficient number of patients with measurement"}]}]}, {"title": "Day 1 hour 2 during infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.388", "spread": "47.476"}]}]}, {"title": "Day 1 hour 16 during infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.004", "spread": "29.713"}]}]}, {"title": "Day 1 hour 22 during infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.774", "spread": "44.219"}]}]}, {"title": "Day 2 hour 32 during infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.472", "spread": "45.060"}]}]}, {"title": "Day 2 hour 40 during infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "35.515", "spread": "36.868"}]}]}, {"title": "Day 2 hour 48 during infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "39.777", "spread": "39.452"}]}]}, {"title": "Day 3 hour 48.5 post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "27.818", "spread": "25.738"}]}]}, {"title": "Day 3 hour 52 post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.014", "spread": "64.862"}]}]}, {"title": "Day 3 hour 56 post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.576", "spread": "78.318"}]}]}, {"title": "Day 14 hour 312 post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "At least one outcome value = 0. Geometric mean is calculated based on the logarithm of the outcome values, and is not populated if any outcome value=0.Geometric CV cannot be calculated due to insufficient number of participants with events"}]}]}, {"title": "Day 28 hour 648 post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "spread": "NA", "comment": "At least one outcome value = 0. Geometric mean is calculated based on the logarithm of the outcome values, and is not populated if any outcome value = 0. Geometric CV cannot be calculated due to insufficient number of participants with events"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Left Arterial Pressure for Low Dose (3-10-30 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study.", "populationDescription": "No data available", "reportingStatus": "POSTED", "timeFrame": "baseline, prior to each dose escalation, and at 24 hr. post end of infusion", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Left Arterial Pressure for High Dose (10 -30-100 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study.", "populationDescription": "No data available", "reportingStatus": "POSTED", "timeFrame": "baseline, prior to each dose escalation, and at 24 hr. post end of infusion", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Pulmonary Artery Pressure (PAP- Systolic and Diastolic) for Low Dose (3-10-30 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "populationDescription": "participants with available data differed across time points", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day3: 24 hours post infusion", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "Baseline diastolic", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "14.0"}]}]}, {"title": "Baseline systolic", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "20.0"}]}]}, {"title": "Day 1 hour 16 diastolic", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-2.0"}]}]}, {"title": "Day 1 hour 16 systolic", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "3.0"}]}]}, {"title": "Day 2 hour 32 diastolic", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "0.0"}]}]}, {"title": "Day 2 hour 32 systolic", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "-2.0"}]}]}, {"title": "Day 2 hour 48 diastolic", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "11.0"}]}]}, {"title": "Day 2 hour 48 systolic", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "6.0"}]}]}, {"title": "Day 3 24 hours post infusiondiastolic", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Day 3 24 hours post infusionsystolic", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Pulmonary Artery Pressure (PAP- Systolic and Diastolic) for High Dose (10-30-100 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "populationDescription": "no data available for any time points", "reportingStatus": "POSTED", "timeFrame": "Day 1: hour 0 and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Central Venous Pressure for Low Dose (3-10-30 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "populationDescription": "participants with available data differed across time points", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.0"}, {"groupId": "OG001", "value": "14.0"}]}]}, {"title": "Day 1 hour 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0"}, {"groupId": "OG001", "value": "2.0"}]}]}, {"title": "Day 2 hour 32", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0"}]}]}, {"title": "Day 2 hour 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0"}]}]}, {"title": "Day 3 24 hours post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Central Venous Pressure for High Dose (10-30-100 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "populationDescription": "participants with available data differed across time points", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.0"}]}]}, {"title": "Day 1 hour 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0"}]}]}, {"title": "Day 2 hour 32", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.0"}]}]}, {"title": "Day 2 hour 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0"}]}]}, {"title": "Day 3 24 hours post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Baseline and Change From Baseline in Mean Central Venous Pressure and Arterial Oxygen Saturation for Low Dose (3-10-30 ug/kg/Day)", "description": "This analysis includes central venous and arterial oxygen saturation measurement, yielding a calculation of the arterio-venous oxygen extraction, where available at each time point. If no arterial access was available, then arterial oxygen saturation measurement data were obtained using a pulse oximeter. The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of oxygen saturation", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "99.5", "spread": "0.71"}, {"groupId": "OG001", "value": "94.0", "spread": "6.56"}, {"groupId": "OG002", "value": "100.0"}]}]}, {"title": "Day 1 our 16", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.5", "spread": "0.71"}, {"groupId": "OG001", "value": "-2.0", "spread": "3.00"}, {"groupId": "OG002", "value": "0.0"}]}]}, {"title": "Day 2 hour 32", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.5", "spread": "2.12"}, {"groupId": "OG001", "value": "1.3", "spread": "1.53"}, {"groupId": "OG002", "value": "-3.0"}]}]}, {"title": "Day 2 hour 48", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.0", "spread": "1.41"}, {"groupId": "OG001", "value": "-0.3", "spread": "1.53"}, {"groupId": "OG002", "value": "-2.0"}]}]}, {"title": "Day 3 - 24 hours post infusion", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.0", "spread": "4.24"}, {"groupId": "OG001", "value": "1.7", "spread": "1.53"}, {"groupId": "OG002", "value": "-3.0"}]}]}]}, {"type": "SECONDARY", "title": "Baseline and Change From Baseline in Mean Central Venous Pressure and Arterial Oxygen Saturation for High Dose (10-30-100 ug/kg/Day)", "description": "This analysis includes central venous and arterial oxygen saturation measurement, yielding a calculation of the arterio-venous oxygen extraction, where available at each time point. If no arterial access was available, then arterial oxygen saturation measurement data were obtained using a pulse oximeter.\n\nThe evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "populationDescription": "participants with available data differed across time points", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of oxygen saturation", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "97.2", "spread": "2.56"}]}]}, {"title": "Day 1 our 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "3.87"}]}]}, {"title": "Day 2 hour 32", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "2.32"}]}]}, {"title": "Day 2 hour 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "2.14"}]}]}, {"title": "Day 3 24 hours post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.2", "spread": "1.92"}]}]}]}, {"type": "SECONDARY", "title": "Baseline and Change From Baseline in Mean Urine Output for Low Dose (3-10-30 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "populationDescription": "participants with available data differed across time points", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/kg/hour", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0"}, {"groupId": "OG001", "value": "1.3", "spread": "1.53"}, {"groupId": "OG002", "value": "1.0"}]}]}, {"title": "Day 1 our 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0"}, {"groupId": "OG001", "value": "0.7", "spread": "1.15"}, {"groupId": "OG002", "value": "0.0"}]}]}, {"title": "Day 2 hour 32", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "3.7", "spread": "4.73"}, {"groupId": "OG002", "value": "-1.0"}]}]}, {"title": "Day 2 hour 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "0.0", "spread": "2.00"}, {"groupId": "OG002", "value": "0.0"}]}]}, {"title": "Day 3 24 hours post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "1.5", "spread": "2.12"}, {"groupId": "OG002", "value": "0.0"}]}]}]}, {"type": "SECONDARY", "title": "Baseline and Change From Baseline in Mean Urine Output for High Dose (10-30-100 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "populationDescription": "participants with available data differed across time points", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/kg/hour", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.2", "spread": "2.48"}]}]}, {"title": "Day 1 our 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.8", "spread": "2.59"}]}]}, {"title": "Day 2 hour 32", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.0", "spread": "5.10"}]}]}, {"title": "Day 2 hour 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "2.70"}]}]}, {"title": "Day 3 24 hours post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.0", "spread": "2.71"}]}]}]}, {"type": "SECONDARY", "title": "Baseline and Change From Baseline in Mean Blood Lactate Levels (Arterial Blood) for Low Dose (3-10-30 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "populationDescription": "participants with available data differed across time points", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.900"}, {"groupId": "OG001", "value": "2.560", "spread": "1.0748"}]}]}, {"title": "Day 1 our 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.100"}, {"groupId": "OG001", "value": "-0.500"}]}]}, {"title": "Day 2 hour 32", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.100"}, {"groupId": "OG001", "value": "-1.100"}]}]}, {"title": "Day 2 hour 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.200"}, {"groupId": "OG001", "value": "-0.900"}]}]}, {"title": "Day 3 24 hours post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Baseline and Change From Baseline in Mean Blood Lactate Levels (Central Venous Blood) for Low Dose (3-10-30 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "populationDescription": "participants with available data differed across time points", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.110"}, {"groupId": "OG001", "value": "2.000"}]}]}, {"title": "Day 1 our 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.333"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Day 2 hour 32", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.222"}]}]}, {"title": "Day 2 hour 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.111"}, {"groupId": "OG001", "value": "0"}]}]}, {"title": "Day 3 24 hours post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.222", "spread": "NA", "comment": "Standard deviation cannot be calculated due to insufficient number of patients with measurement"}]}]}]}, {"type": "SECONDARY", "title": "Baseline and Change From Baseline in Mean Blood Lactate Levels (Arterial Blood) for High Dose (10-30-100 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "populationDescription": "participants with available data differed across time points", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.300"}]}]}, {"title": "Day 1 our 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.100"}]}]}, {"title": "Day 2 hour 32", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.200"}]}]}, {"title": "Day 2 hour 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.300"}]}]}, {"title": "Day 3 24 hours post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Baseline and Change From Baseline in Mean Blood Lactate Levels (Central Venous Blood) for High Dose (10-30-100 ug/kg/Day)", "description": "The evaluations, as available, were done at baseline, prior to each dose escalation and at approximately 24 hours after the end of the infusion. Hemodynamic effects were also assessed for safety at additional time points during the study. Absolute values are presented at baseline; change from baseline values are presented at post-baseline time points", "populationDescription": "participants with available data differed across time points", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "Day 1: hour 0 (Baseline) and 16, Day 2: hour 32 and 48, Day 3: 24 hours post infusion", "groups": [{"id": "OG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients."}, {"id": "OG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"title": "Baseline", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.200"}]}]}, {"title": "Day 1 our 16", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.600", "spread": "NA", "comment": "Standard deviation cannot be calculated due to insufficient number of patients with measurement"}]}]}, {"title": "Day 2 hour 32", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Day 2 hour 48", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.200", "spread": "NA", "comment": "Not available due to insufficient number of patients with measurement"}]}]}, {"title": "Day 3 24 hours post infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0.5", "timeFrame": "Adverse events and serious adverse events were collected for the maximum actual duration of treatment exposure and follow-up (i.e. approximately 28 days) for the participants per protocol", "eventGroups": [{"id": "EG000", "title": "Serelaxin: Cohort 1", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 1, patients in age group of 6 to \\<18 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients.", "deathsNumAffected": 0, "deathsNumAtRisk": 8, "seriousNumAffected": 3, "seriousNumAtRisk": 8, "otherNumAffected": 6, "otherNumAtRisk": 8}, {"id": "EG001", "title": "Serelaxin: Cohort 2", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 2, patients in age group of 1 to \\<6 years were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. Both the low-dose and high- dose groups were planned to receive equal number of patients.", "deathsNumAffected": 0, "deathsNumAtRisk": 3, "seriousNumAffected": 1, "seriousNumAtRisk": 3, "otherNumAffected": 3, "otherNumAtRisk": 3}, {"id": "EG002", "title": "Serelaxin: Cohort 3", "description": "Serelaxin was administered intravenously on top of standard therapy for acute heart failure, for a total of 48 hours. In Cohort 3, patients in age group of 1 month to \\<1 year were enrolled either into a low-dose or a high-dose group. During this 48-hour treatment period, the serelaxin dose rates to be administered were 3 \u03bcg/kg/day, 10 \u03bcg/kg/day and 30 \u03bcg/kg/day in the low -dose group; 10 \u03bcg/kg/day, 30 \u03bcg/kg/day and 100 \u03bcg/kg/day in the high-dose group. In this cohort, high- dose group was planned to receive twice the number of patients in low-dose group.", "deathsNumAffected": 0, "deathsNumAtRisk": 1, "seriousNumAffected": 0, "seriousNumAtRisk": 1, "otherNumAffected": 0, "otherNumAtRisk": 1}], "seriousEvents": [{"term": "Atrial thrombosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Pericardial effusion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Subclavian vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Vena cava thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}], "otherEvents": [{"term": "Supraventricular extrasystoles", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Pneumonia viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Procedural pain", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Blood pressure systolic decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Cardioactive drug level increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Hypochloraemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Hyperhidrosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Night sweats", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Skin oedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (20.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 8}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 3}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 1}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Due to the early termination of the study, the planned analyses were not performed as the limited set of data would preclude meaningful interpretation."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "email": "novartis.email@novartis.com", "phone": "862-778-8300"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2016-09-30", "uploadDate": "2017-09-27T13:49", "filename": "Prot_000.pdf", "size": 596348}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2018-08-09", "uploadDate": "2019-04-24T14:00", "filename": "SAP_001.pdf", "size": 370406}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Canada"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}}, "hasResults": true}